Long-Term Safety Of Fixed-Dose Combination Aclidinium Bromide/formoterol Fumarate In Patients With Moderate To Severe COPD: The Augment COPD Extension Trial

被引：0
|
作者：
Rennard, S. I. [1 ]
D'Urzo, A. D. [2 ]
Donohue, J. F. [3 ]
He, T. [4 ]
Shrestha, P. [4 ]
Leselbaum, A. [5 ]
Caracta, C. [4 ]
机构：
[1] Univ Nebraska Med Ctr, Omaha, NE USA
[2] Univ Toronto, Toronto, ON, Canada
[3] Univ N Carolina, Chapel Hill, NC USA
[4] Forest Res Inst, Jersey City, NJ USA
[5] Almirall SA, Barcelona, Spain
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2014年 / 189卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A6008
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Comparative efficacy and safety of glycopyrronium/formoterol fixed-dose combination versus glycopyrronium monotherapy in patients with moderate-to-severe COPD
    Salvi, Sundeep
    Jain, Manish K.
    Krishnamurthy, Srikanth
    Balki, Akash
    Kodgule, Rahul
    Tandon, Monika
    Bhagat, Sagar
    Panchal, Sagar
    Khatri, Nishtha
    Wu, Wen
    Pendse, Amol
    Patil, Saiprasad
    Barkate, Hanmant
    LUNG INDIA, 2022, 39 (06) : 517 - 524
  • [42] Cardiovascular (CV) safety of aclidinium bromide/formoterol fumarate fixed dose combination (FDC) in COPD: Pooled analyses of three Phase III studies
    Donohue, James F.
    Bateman, Eric D.
    D'Urzo, Anthony
    Shrestha, Pomy
    Leselbaum, Anne
    Lei, Alejhandra
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [43] Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial
    Tashkin, Donald P.
    Doherty, Dennis E.
    Kerwin, Edward
    Matiz-Bueno, Carlos E.
    Knorr, Barbara
    Shekar, Tulin
    Banerjee, Sibabrata
    Staudinger, Heribert
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2012, 7 : 43 - 55
  • [44] Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease
    Babu, K. Suresh
    Morjaria, Jaymin B.
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (02) : 56 - 68
  • [45] The Efficacy And Safety Of Aclidinium/formoterol Fixed-Dose Combination Compared With Salmeterol/fluticasone In Patients With COPD: Results From A Phase Iii Study
    Vogelmeier, C.
    Paggiaro, P.
    Dorca, J.
    Sliwinski, P.
    Mallet, M.
    Kirsten, A. -M.
    Seoane, B.
    Segarra, R.
    Leselbaum, A.
    Garcia Gil, E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [46] Effects of twice-daily aclidinium bromide in COPD patients: A long-term extension of ACCORD-COPD
    D'Urzo, Anthony
    Kerwin, Edward
    Donohue, James
    Rennard, Stephen
    Gelb, Arthur
    Lakkis, Hassan
    Garcia Gil, Esther
    Caracta, Cynthia
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [47] Lung function with aclidinium/formoterol fixed-dose combination: Pooled analysis of two phase III studies in COPD
    Singh, Dave
    D'Urzo, Anthony D.
    Donohue, James F.
    Chuecos, Ferran
    Leselbaum, Anne
    Garcia Gil, Esther
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [48] Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD
    Gelb, Arthur F.
    Tashkin, Donald P.
    Make, Barry J.
    Zhong, Xiaoyun
    Garcia Gil, Esther
    Caracta, Cynthia
    RESPIRATORY MEDICINE, 2013, 107 (12) : 1957 - 1965
  • [49] Evaluation Of Major Adverse Cardiovascular Events And COPD Exacerbations In A Long-Term Study Of Aclidinium Bromide In Patients With Moderate To Very Severe COPD: Ascent COPD Rationale And Design
    Wise, R. A.
    Rekeda, L.
    D'Andrea, C.
    Shrestha, P.
    Caracta, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [50] EFFICACY AND SAFETY OF ONCE-DAILY ACLIDINIUM BROMIDE 200 μG IN COMBINATION WITH FORMOTEROL IN PATIENTS WITH COPD
    Sliwinski, P.
    Perng, D-W
    Chuchalin, A.
    Jones, P. W.
    THORAX, 2010, 65 : A136 - A136
12345